medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2015, Number 1

<< Back Next >>

Residente 2015; 10 (1)

Anticuerpos antipéptido citrulinado cíclico (anti-CCP) en artritis reumatoide

Casillas-Iglesias FI, Bonilla-Lara D, Murillo-Vázquez JD, Corona-Sánchez EG, Contreras-Moreno MG, Saucedo-Ulloa M, Saldaña-Anguiano JM, González-López L

Language: Spanish
References: 27
Page: 12-17
PDF size: 212.33 Kb.


ABSTRACT

Rheumatoid arthritis (RA) is a progressive systemic autoimmune inflammatory chronic disease of unknown etiology, leading to a structural joint damage, functional impairment and reduced quality of life. Its prevalence is 23% in Latin America; in Mexico, 1.6% of adults suffer from it, which makes it the main reason for consultation in the rheumatology service. In the last 10 years, changes have occurred in the landscape of this disease, such as biomarkers of RA, with the appearance and standardization of anti-cyclic citrullinated peptide antibodies (anti-CCP), which were included in the diagnostic criteria of 2010, with the advantage of allowing early diagnosis of RA, as they are applied to a group of patients with recent-onset synovitis, are positive in 40% of seronegative RA patients and only appear in 2-5% of patients with rheumatic diseases other than RA. Positivity anti-CCP is related to greater structural damage, greater radiographic progression and a more severe course of the disease. This review presents the known evidence about anti-CCP in the diagnosis of rheumatoid arthritis.


REFERENCES

  1. Bingham CO, 3rd. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. The Journal of Rheumatology Supplement. 2002; 65: 3-9.

  2. Schneider M, Kruger K. Rheumatoid arthritis –early diagnosis and disease management. Deutsches Arzteblatt International. 2013; 110 (27-28): 477-484.

  3. Basra G, Jajoria P, Gonzalez E. Rheumatoid arthritis and swine influenza vaccine: a case report. Case Reports in Rheumatology. 2012; 2012: Article ID 785028.

  4. Pelaez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumat Suppl. 2011; 86: 3-8.

  5. Sanchez-Ramon S, Lopez-Longo FJ, Carreno L. [Interleukins network in rheumatoid arthritis pathophysiology: beyond proinflammatory cytokines]. Reumatol Clin. 2011; 6s3: S20-S24.

  6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31 (3): 315-324.

  7. Gabriel SE, Crowson CS, O’Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum. 1999; 42 (3): 415-420.

  8. Carmona L, Villaverde V, Hernandez-Garcia C, Ballina J, Gabriel R, Laffon A. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford, England). 2002; 41 (1): 88-95.

  9. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62 (9): 2569-2581.

  10. Gómez A. Anticuerpos anti-PCC. Titlerevista. 2005; 32 (03): 85-87.

  11. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis. 1964; 23: 302-305.

  12. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. British Medical Journal. 1979; 2 (6182): 97-99.

  13. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. The Journal of Clinical Investigation. 1998; 101 (1): 273-281.

  14. Van Venrooij WJ, Pruijn GJ. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Research. 2000; 2 (4): 249-251.

  15. Baka Z, Gyorgy B, Geher P, Buzas EI, Falus A, Nagy G. Citrullination under physiological and pathological conditions. Joint, Bone, Spine: Revue Du Rhumatisme. 2012; 79 (5): 431-436.

  16. Balsa A, Pascual-Salcedo D, Martin J. Antibodies to citrullinated peptides in rheumathoid arthritis. Medicina Clínica. 2007; 128 (17): 668-673.

  17. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004; 50 (2): 380-386.

  18. Kinloch A, Lundberg K, Wait R, Wegner N, Lim NH, Zendman AJ et al. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum. 2008; 58 (8): 2287-2295.

  19. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000; 43 (1): 155-163.

  20. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007; 146 (11): 797-808.

  21. Van Gaalen F, Ioan-Facsinay A, Huizinga TW, Toes RE. The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. J Immunol. 2005; 175 (9): 5575-5580.

  22. Van Venrooij WJ, Vossenaar ER, Zendman AJ. Anti-CCP antibodies: the new rheumatoid factor in the serology of rheumatoid arthritis. Autoimmunity Reviews. 2004; 3 (Suppl 1): S17-S19.

  23. Zendman AJ, van Venrooij WJ, Pruijn GJ. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology. 2006; 45 (1): 20-25.

  24. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006; 65 (7): 845-851.

  25. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003; 62 (2): 120-126.

  26. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000; 43 (8): 1831-1835.

  27. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004; 63 (12): 1587-1593.




2020     |     www.medigraphic.com